本届展会汇集了覆盖全国等级医院、零售药店、医药电商、基层医疗终端等全渠道的专业资源与合作伙 伴，吸引了来自政府机构、行业组织、产业园区、医药工业及相关服务业等专业观众参观、洽谈。"专 区专展"的展出模式更是极大程度地凝聚目标观众，展会一大亮点即是创新设立了"高增长渠道专区"， 精准锚定基层医疗与医药新零售两大高潜力赛道，旨在为企业破解渠道拓展困局提供一个精准、高效、 系统化的解决方案。 展会同期举办超过30+场热点主题会议论坛，涵盖商业流通、市场营销、政策法规、中医药、国际化、 研发创新、零售、热点赛道等模块。贴近市场新机遇的10+场特备活动，包括高增长渠道系列活动、中 医药主题系列活动、首发经济系列活动等。在精心策划的一系列创新互动活动中，"新耀登场"新品首发 show作为展会倾力打造的年度新品首发阵地，为行业注入了创新活力。重磅会议与多彩活动成为焦 点，参与人员络绎不绝，彰显了中国医药健康产业的蓬勃活力。 11月19日至21日，第91届全国药品交易会（PHARMCHINA）、中医药博览会、中国药店采购供应博览 会携手2025中国国际健康营养博览会（NHNE）重磅亮相南京国际博览中心。 作为中国医药制剂与大 ...

Group 1: Chronic Disease Management in China - The incidence of chronic non-communicable diseases is significantly increasing in China due to rapid economic and social development and an aging population, leading to higher disability rates, mortality rates, and medical costs [1] - The "Healthy China 2030" plan aims to achieve comprehensive chronic disease health management for the entire population and lifecycle by 2030, requiring a series of integrated measures for prevention and control [1] - By 2027, counties (cities, districts) that develop close-knit medical alliances are expected to achieve full-process health management services for chronic diseases at the grassroots level [1] Group 2: COPD and Its Management - Chronic Obstructive Pulmonary Disease (COPD) is a major health concern in China, with nearly 100 million patients, particularly affecting those over 40 years old [3][4] - Early screening, diagnosis, and standardized treatment are crucial for managing COPD, with lung function tests being a key diagnostic method [3][4] - The public awareness of COPD is alarmingly low, with less than 10% of the population aware of the disease, and only about 3% of patients knowing their diagnosis [4] Group 3: Market Dynamics and Growth - The global chronic disease drug market is projected to reach $1.25 trillion in 2024, with China's market expected to reach 685 billion RMB, accounting for 14.3% of the global market [6] - The growth is driven by an aging population, improved early diagnosis rates, and expanded health insurance coverage [6] - The chronic disease drug market in China is characterized by high concentration, high growth, and high innovation, with diabetes drug market growth leading at 14.2% [6] Group 4: AstraZeneca's Strategic Focus - AstraZeneca has been active in the respiratory drug market since the 1990s, introducing various inhalation products for asthma and COPD [7] - The company is undergoing a strategic transformation towards biologics, with a focus on developing innovative treatments for chronic respiratory diseases [7][10] - AstraZeneca aims to enhance accessibility to COPD treatment in grassroots healthcare settings, addressing high misdiagnosis and underdiagnosis rates [8][11] Group 5: Policy and Collaborative Efforts - The Chinese government has implemented policies to improve early screening, diagnosis, and treatment capabilities for chronic respiratory diseases [11] - AstraZeneca is collaborating with local healthcare providers to support the establishment of disease management centers and enhance the capabilities of community health services [8][11] - The company's efforts align with the "Healthy China 2030" initiative, aiming to provide better healthcare services for chronic disease patients [11]

Core Viewpoint - Sichuan Good Doctor Cloud Medical Technology Group Co., Ltd. has submitted its listing application to the Hong Kong Stock Exchange, with Haitong International and CITIC Securities as joint sponsors [1] Company Overview - Good Doctor Cloud Medical is a leading comprehensive grassroots medical empowerment platform in China, aiming to provide high-quality medical resources to grassroots markets, allowing local residents to access tertiary hospital-level medical services and products [5] - The company ranks second in China's grassroots medical empowerment service industry based on revenue as of 2024 [7] Market Position - As of June 30, 2025, Good Doctor Cloud Medical has directly served over 660,600 grassroots medical terminal customers, including over 389,300 grassroots medical institutions and 271,300 grassroots pharmacies [8] - The company is the only comprehensive empowerment platform in China's grassroots medical industry that utilizes digital intelligence and AI assistance, offering integrated solutions covering testing, diagnosis, medication, and treatment [7][8] Customer Growth - The number of registered grassroots medical terminal customers has grown at a compound annual growth rate (CAGR) of 29.0% from December 31, 2022, to December 31, 2024 [9] - The average monthly paying customer count increased from over 83,800 in 2022 to over 121,900 in 2024, reflecting a CAGR of 20.6% [9] Industry Insights - The grassroots medical industry in China is substantial, consisting of approximately 1.636 million grassroots medical terminals, including about 1.04 million grassroots medical institutions and 291,000 single pharmacies [9] - The market size of China's grassroots medical industry is projected to reach RMB 544.5 billion in 2024, with an expected CAGR of 9.2% from 2024 to 2030, reaching RMB 922 billion by the end of 2030 [9] Financial Performance - For the fiscal years ending June 30, 2023, 2024, and 2025, the company reported revenues of approximately RMB 3.065 billion, RMB 3.264 billion, and RMB 1.891 billion, respectively [10] - The profits for the same periods were RMB 62.48 million, RMB 37.81 million, and RMB 35.77 million, respectively [10]

Group 1 - The event "2025 Most Beautiful Grassroots Doctors Recommendation and Display" has been officially launched to promote respect for medical professionals and enhance grassroots healthcare services [1][2] - Good Doctor Group and Shenyang Qinggong Pharmaceutical Group are key supporters of the event, aiming to create a positive environment for grassroots healthcare and recognize the contributions of grassroots doctors [2][3] - The initiative seeks to establish a platform for professional development and skill enhancement for grassroots doctors, fostering a culture of respect and recognition within society [3][4] Group 2 - Good Doctor Group has been dedicated to grassroots healthcare development, focusing on "caring for public health" and "industry feeding back to public welfare" since its establishment [4] - The company has launched a large-scale public welfare project for training rural doctors, emphasizing a comprehensive training system that includes knowledge empowerment and hardware support [4][5] - Shenyang Qinggong Pharmaceutical aims to enhance grassroots medical capabilities while preserving traditional Chinese medicine, participating in various academic and training activities to support grassroots healthcare [5][6] Group 3 - The selection process for the event includes self-nominations, unit recommendations, and media recommendations, with a final list determined through public opinion screening and field research [5][6] - The event encourages grassroots medical workers to submit their materials for evaluation, with selected individuals invited to an annual summary and awards ceremony [5][6]

Core Points - The event "2024 Most Beautiful Grassroots Doctors Recommendation and Display Activity" was held in Beijing, highlighting the contributions of grassroots medical workers in improving public health [1][2] - The average life expectancy in China has significantly increased, attributed to the dedication of grassroots healthcare workers [2] - The event aims to promote the stories and virtues of grassroots doctors, encouraging more social support for grassroots healthcare initiatives [2][3] Group 1 - The "2024 Most Beautiful Grassroots Doctors Recommendation and Display Activity" was organized by the China Medical News Information Association, with support from People's Health and various pharmaceutical companies [1][3] - Grassroots doctors are recognized as the guardians of public health, and their stories of dedication and compassion are emphasized as deserving of wider recognition [2] - The event included the announcement of 100 recommended grassroots medical workers, showcasing their contributions to community health [3][4] Group 2 - The event featured industry experts and leaders who acknowledged the importance of social support for grassroots healthcare [3] - Future activities will continue to focus on recognizing and supporting grassroots medical workers, with plans for the 2025 annual event already in motion [3][4] - The commitment of companies like Good Doctor Group to support grassroots healthcare through training and development initiatives was highlighted [2]